Cargando…

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations

Failure of antiretroviral regimens containing elvitegravir (EVG) and raltegravir (RAL) can result in the appearance of integrase inhibitor (INI) drug-resistance mutations (DRMs). While several INI DRMs have been identified, the evolution of EVG DRMs and the linkage of these DRMs with protease inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winters, Mark A., Lloyd, Robert M., Shafer, Robert W., Kozal, Michael J., Miller, Michael D., Holodniy, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399858/ https://www.ncbi.nlm.nih.gov/pubmed/22815755 http://dx.doi.org/10.1371/journal.pone.0040514

Ejemplares similares

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility
por: Varghese, Vici, et al.
Publicado: (2016)

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)
por: DeVos, Joshua, et al.
Publicado: (2022)

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
por: Siedner, Mark J., et al.
Publicado: (2020)

Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq
por: Dudley, Dawn M, et al.
Publicado: (2014)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2020)

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness
por: Martin, Supang A., et al.
Publicado: (2021)

Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings
por: Manyana, Sontaga, et al.
Publicado: (2023)

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
por: Reuman, Elizabeth C., et al.
Publicado: (2010)

MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors
por: Aralaguppe, Shambhu G., et al.
Publicado: (2019)

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance
por: Wainberg, Mark A.
Publicado: (2012)

HIV-1 5’-Leader Mutations in Plasma Viruses Before and After the Development of Reverse Transcriptase Inhibitor-Resistance Mutations
por: Nouhin, Janin, et al.
Publicado: (2023)

Interactions of different drug resistance mutations in HIV Reverse Transcriptase in defining patterns of drug resistance
por: Wainberg, Mark A
Publicado: (2011)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation
por: Rhee, Soo-Yon, et al.
Publicado: (2007)

Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina
por: Cecchini, Diego, et al.
Publicado: (2021)

Cis-Allosteric Regulation of HIV-1 Reverse Transcriptase by Integrase
por: Masuda, Takao, et al.
Publicado: (2022)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals
por: Bokharaei-Salim, Farah, et al.
Publicado: (2020)

Genetic and antiretroviral drug resistance mutations analysis of reverse transcriptase and protease gene from Pakistani people living with HIV-1
por: Siddiqui, Dilsha, et al.
Publicado: (2023)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland
por: Smoleń-Dzirba, Joanna, et al.
Publicado: (2017)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
por: Babrzadeh, Farbod, et al.
Publicado: (2013)

HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination
por: Nishana, Mayilaadumveettil, et al.
Publicado: (2017)

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
por: Abram, Michael E., et al.
Publicado: (2017)

Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
por: Masso, Majid, et al.
Publicado: (2013)

Distinguishing Functional Amino Acid Covariation from Background Linkage Disequilibrium in HIV Protease and Reverse Transcriptase
por: Wang, Qi, et al.
Publicado: (2007)

Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment
por: Michels, I, et al.
Publicado: (2010)

Prediction of Mutational Tolerance in HIV-1 Protease and Reverse Transcriptase Using Flexible Backbone Protein Design
por: Humphris-Narayanan, Elisabeth, et al.
Publicado: (2012)

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
por: Singh, Kamal, et al.
Publicado: (2019)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Structural coordination between active sites of a CRISPR reverse transcriptase-integrase complex
por: Wang, Joy Y., et al.
Publicado: (2021)

Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients
por: Kapoor, Amit, et al.
Publicado: (2008)

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
por: Blanco, Jose-Luis, et al.
Publicado: (2011)

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo dynamics of integrase inhibitor resistance mutations
por: Nguyen, Nga, et al.
Publicado: (2013)

Mutation Rates and Intrinsic Fidelity of Retroviral Reverse Transcriptases
por: Menéndez-Arias, Luis
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lqa4gle5i9plmodt903eoj1obh